Audio Coursesby JellypodLesson 10 of 15
Overview
Explore sedation practices from emergency departments to ICUs across three countries, debunking myths and examining real-world challenges. Delve into the complexities of drug choice, training protocols, and data-driven safety in high-stakes care environments.
Hamish: Welcome to The TIME Podcast. I’m Hamish.
Jeremy: And I’m Jeremy.
Hamish: For those of you joining us for the first time, TIME is a podcast and a conference series created by Clintix, focused on the real-world intersection of technology, innovation, medicine, and evidence. This isn’t about shiny tools or early hype. It’s about how change actually lands on the floor — in emergency departments, ICUs, retrieval services, and across health systems.
Hamish: And that’s very much the spirit of the TIME Conference, which Clintix also hosts. The goal isn’t consensus. It’s an informed disagreement. The kind of conversation that carries on after the session ends — in the corridor, over coffee, or on the flight home.
Jeremy: So if you’re listening for neat answers, you might be disappointed. But if you’re listening to sharpen how you think about risk, systems, and responsibility, you’re in the right place.
Hamish: Today, we’re turning our attention to something that looks, on the surface, like a settled problem: pediatric procedural sedation.
Jeremy: Because if you look at the last five years of data across Australia and New Zealand, the UK, and the United States, the headline is almost boringly reassuring. Tens of thousands of sedations. Extremely low rates of serious adverse events. Near-zero mortality. No signal of widespread harm.
Hamish: Which should make us pause.
Jeremy: Exactly. Because whenever medicine looks this safe, this routine, the risk is that we stop asking why it’s safe — and what’s actually holding that safety together.
Hamish: And more importantly, where the risk has gone. Because risk never disappears. It just moves. It shifts between people, departments, professions, and sometimes institutions.
Jeremy: The material we’re drawing on today compares pediatric procedural sedation practices across three regions — Australia/New Zealand, the UK, and the US — looking at emergency departments, ICU-led sedation, and anesthesiology-led models. The data are robust in places, thinner in others, and revealing in ways that aren’t immediately obvious.
Hamish: And the more you sit with it, the clearer it becomes that this isn’t really a story about ketamine versus propofol, or nitrous versus nothing. It’s a story about systems. About rescue capability. About governance. About who owns the airway when things drift, and who absorbs the consequences when sedation is asked to solve problems it was never designed to fix.
Jeremy: So rather than asking, “Is pediatric procedural sedation safe?” — which the data largely answer — we want to ask a more uncomfortable question: What kind of system do you need to make it safe, and what trade-offs are you making along the way?
Hamish: And to get there, we need to start with context. Because the way sedation is practised — and the way risk is managed — looks very different depending on where you stand.
Jeremy: So let’s start there.
Jeremy: One of the most striking things in the data is how normalised pediatric procedural sedation is across all three regions — but how differently it’s actually delivered.
Hamish: Yes. On paper, Australia, the UK, and the US all report excellent safety outcomes. But the routes they take to get there couldn’t be more different. And those differences tell you a lot about how each system thinks about risk.
Jeremy: Take Australia and New Zealand first. If you walk into a tertiary pediatric emergency department, or indeed most Emergency Departments, procedural sedation is very clearly an ED-owned activity. Emergency physicians are expected to do it. Nitrous oxide is everywhere. Ketamine is routine. Anesthetics are the exception, not the default.
Hamish: And that’s not accidental. It reflects a system that values speed, decisiveness, and minimising theatre dependence. Nitrous oxide isn’t just a sedative choice — it’s a workflow decision. It keeps kids out of theatre, keeps beds moving, and avoids escalating to general anaesthesia unless absolutely necessary.
Jeremy: And the outcomes support that approach. High procedural success rates. Very low serious complication rates. Mostly minor events — vomiting, transient desaturation, agitation — all managed on the floor.
Hamish: But there’s an important cultural assumption baked into that model: that ED clinicians own the airway if things drift. That they’re trained, resourced, and psychologically prepared to rescue when sedation deepens unexpectedly.
Jeremy: Which brings us neatly to the UK — because the UK historically made a very different bargain
Hamish: Yes. The UK’s relationship with pediatric sedation has been… cautious. Even suspicious. For years, there was a strong preference to involve anesthesiology early, or to default to general anaesthesia rather than deep sedation outside theatre.
Jeremy: That caution didn’t come from nowhere. It was shaped by earlier adverse events, national reviews, and a strong emphasis on governance and accountability. The implicit message was: if sedation goes wrong, the system wants someone whose primary identity is airway management holding that risk.
Hamish: And even now, as ED ketamine sedation has expanded in the UK, it’s often tightly protocolised. Consultant presence. Strict monitoring requirements. Clear escalation pathways. The autonomy exists, but it’s conditional.
Jeremy: Which leads to an interesting paradox. UK EDs perform fewer sedations than their Australian counterparts — but when they do, the safety record is just as strong.
Hamish: Because the system has effectively said: we’ll allow this, but only if the scaffolding is visible. The risk isn’t denied — it’s tightly supervised.
Jeremy: Then you look at the United States, and it’s almost a third philosophy altogether.
Hamish: Absolutely. The US response to sedation risk has been industrial. Registries. Dedicated sedation services. Credentialing pathways. Quality dashboards. The Pediatric Sedation Research Consortium alone has data on hundreds of thousands of cases.
Jeremy: Which allows a broader range of providers — intensivists, hospitalists, ED physicians — to deliver deep sedation, often with propofol, often outside the OR, but within a highly structured governance framework.
Hamish: And crucially, with a constant feedback loop. Adverse events aren’t just managed — they’re counted, classified, and fed back into system design.
Jeremy: So you end up with three distinct safety strategies. Australia relies on simplicity and clinician versatility. The UK relies on conservative thresholds and specialist oversight. The US relies on scale, data, and formalised rescue capability.
Jeremy: All of them work — in the sense that kids are overwhelmingly safe.
Jeremy: But they distribute risk very differently.
Hamish: Exactly. In Australia, the ED absorbs it. In the UK, anesthesiology absorbs it. In the US, the system tries to spread it through teams, protocols, and data.
Jeremy: And this is where the conversation starts to matter for leaders. Because none of these models is free. Each one requires investment — in training, staffing, governance, or throughput capacity.
Hamish: And each one has failure modes. The Australian model strains clinicians if support erodes. The UK model risks overuse of GA and theatre bottlenecks. The US model risks complexity, credentialing creep, and diffusion of responsibility.
Jeremy: So before we even talk about drugs or adverse events, the real question is: which cultural bargain is your system making — consciously or not?
Hamish: And whether that bargain still holds under current pressures.
Jeremy: With that context in mind, we should zoom in to where most of this actually plays out day to day.
Hamish: The emergency department.
Jeremy: Because that’s where sedation is asked to do the most work — often with the least margin.
Jeremy: If there’s one place where pediatric procedural sedation has been truly normalised, it’s the emergency department. Not as a special event. Not as a once-a-week occurrence. But as part of the everyday operating rhythm.
Hamish: And that normalisation is exactly why it deserves scrutiny. Because in the ED, sedation is often framed as low risk — especially when we’re talking about nitrous oxide or ketamine.
Jeremy: The data encourage that framing. Across all three regions, ED sedation has very high success rates and very low rates of serious complications. Intubation is rare. Aspiration is almost unheard of. Mortality is essentially zero.
Hamish: But “low risk” is doing a lot of work in that sentence.
Jeremy: Explain that.
Hamish: Because the ED model depends on a series of assumptions that usually hold — until they don’t. The child is relatively well. The procedure is short. That the clinician managing sedation isn’t simultaneously managing something else. That escalation is immediately available if needed.
Jeremy: And in practice, those assumptions are increasingly stretched.
Hamish: Exactly. Take nitrous oxide, particularly in Australia and New Zealand. It’s elegant. Rapid onset, rapid offset, minimal physiological disturbance. For brief procedures, it’s hard to beat.
Jeremy: But it also creates a cognitive shortcut. Nitrous starts to feel like “not really sedation.” More like analgesia-plus. Which subtly lowers vigilance.
Hamish: Right. You don’t call for backup. You don’t mentally rehearse airway rescue. You don’t always have a second clinician whose only job is to watch the child. And most of the time, nothing happens — which reinforces the behaviour.
Jeremy: Ketamine sits in a slightly different psychological space. It’s more obviously a sedative. People respect it.
Hamish: They do — but they also trust it. Ketamine’s reputation for preserving airway reflexes has become almost mythic. And to be fair, the data support its relative safety when used as a single agent.
Jeremy: Single agent being the key phrase.
Hamish: Yes. Because the moment ketamine is combined with opioids, benzodiazepines, or propofol, the risk profile shifts. Not dramatically, but meaningfully. And those combinations tend to creep in when procedures get longer, or when the child is more distressed, or when the operator wants “just a bit more depth.”
Jeremy: Which is often when the ED is busiest.
Hamish: Exactly. The real-world failure mode isn’t reckless dosing. It’s incremental escalation under pressure. One more milligram. One more drug. One more attempt to avoid calling anesthesia or delaying care.
Jeremy: And yet, when we look at the adverse event data, the ED still performs remarkably well.
Hamish: Because rescue works. Brief apnea. Transient desaturation. Jaw thrust. Bag-mask ventilation. Everyone breathes again. Event closed.
Jeremy: But those moments rarely make it into governance conversations.
Hamish: No. They’re filed away as “expected,” “managed,” or left undocumented. Which means leadership often sees a dashboard that says: no serious adverse events — all good.
Jeremy: When in reality, clinicians are absorbing a steady stream of near-misses.
Hamish: And adapting to them. Quietly. Skillfully. Sometimes heroically. But adaptation has a cost.
Jeremy: This is where I’ll push back slightly. You could argue that this adaptability is exactly what makes ED sedation safe. Clinicians are used to managing uncertainty. They’re good at it.
Hamish: I don’t disagree — but I worry about relying on that as a design principle. Because adaptability isn’t infinite. And it’s unevenly distributed. It depends on experience, staffing, time of day, and local culture.
Jeremy: So the myth isn’t that ED sedation is unsafe.
Hamish: No. The myth is that it’s inherently low risk, independent of context. The risk is low because people are constantly working to keep it low.
Jeremy: Which raises an uncomfortable question for leaders.
Hamish: Yes. If your ED sedation outcomes look excellent, is that because the system is well designed — or because your clinicians are compensating for gaps you don’t see?
Jeremy: And what happens when those clinicians are tired, junior, or stretched thinner than before?
Hamish: Or when sedation is asked to solve throughput problems rather than clinical ones.
Jeremy: That feels like a good point to pause — because it brings us to a setting where rescue capability is more explicit, and escalation is built in by design.
Hamish: The ICU.
Jeremy: Where sedation safety is achieved in very different ways.
Jeremy: If the emergency department model relies on versatility and speed, the ICU model is built around something else entirely.
Hamish: Rescue.
Jeremy: Exactly. In the ICU, pediatric procedural sedation isn’t framed as “low risk.” It’s framed as controlled risk. The assumption is not that nothing will go wrong — it’s that when something goes wrong, the system is already standing in the room.
Hamish: And that fundamentally changes behaviour. ICU clinicians are comfortable with deeper sedation. Propofol doesn’t scare them. Ketamine is used strategically. Dexmedetomidine comes into play. There’s far less psychological resistance to crossing into what looks suspiciously like general anaesthesia.
Jeremy: Because escalation isn’t failure — it’s part of the plan.
Hamish: Right. Airway equipment is there. Skilled staff are there. Vasopressors, ventilators, capnography — it’s all normalised. So the threshold to proceed with sedation is lower, even for more complex or physiologically fragile children.
Jeremy: And the outcomes, at least from the registry data we have, look excellent. Very high procedural success rates. Very low mortality. Extremely rare catastrophic events.
Hamish: But this is where evidence honesty matters. Most of what we know about ICU-led pediatric sedation comes from large observational registries, particularly in the US. They’re impressive datasets — but they’re not randomised, and they’re not immune to selection bias.
Jeremy: Meaning the sickest kids, the weird airways, the truly high-risk cases are often filtered out to anesthesiology or full general anaesthesia
Hamish: Exactly. So the ICU model looks incredibly safe — in part because it’s very good at choosing its battles.
Jeremy: That said, the ICU also reveals a different kind of failure mode.
Hamish: Yes. And this is where I think ICU clinicians will recognise themselves.
Jeremy: Go on.
Hamish: Picture this. Non-intubated child in PICU. Needs a line, or a dressing change, or imaging. Propofol infusion started. Everyone’s relaxed — until the child obstructs. Saturations dip. Jaw thrust, bagging, all fine. Child recovers. Procedure continues.
Jeremy: A near-miss.
Hamish: Exactly. And here’s the key question: was that a complication, or was that expected physiology?
Jeremy: Most ICUs would say the latter.
Hamish: And that’s the danger. Because when rescue is so effective, it stops feeling like a failure signal. It becomes background noise. Something you deal with and move on from.
Jeremy: Which means it often doesn’t travel upwards. It doesn’t trigger a review. It doesn’t appear in governance reports.
Hamish: Right. From the system’s perspective, nothing went wrong. No intubation. No arrest. No incident report. Green lights across the board.
Jeremy: But from a human factors perspective, that moment matters. It’s a point where the system briefly stepped off the edge and was pulled back by skill and vigilance.
Hamish: And that vigilance has a cost. Cognitive load. Emotional load. The need to stay “on” throughout what might otherwise feel like a routine procedure.
Jeremy: This is where I’ll challenge you slightly. Isn’t that exactly what ICU is designed for? High-risk tolerance. Continuous monitoring. Managing physiologic drift.
Hamish: Yes — but only if we’re honest about what we’re asking the ICU to absorb. Because increasingly, ICU-led sedation isn’t just about ICU patients. It’s about system overflow. Theatre access issues. Imaging backlogs. Staffing constraints elsewhere.
Jeremy: So sedation becomes a pressure valve.
Hamish: Exactly. And pressure valves work — until they don’t. The risk isn’t that ICU sedation is unsafe. The risk is that its apparent safety enables systems to lean on it harder and harder.
Jeremy: Which raises a governance question.
Hamish: A big one. Who decides when ICU sedation is appropriate versus when a child should go to theatre? Is that a clinical decision, or a capacity decision?
Jeremy: And who owns the risk when that decision is influenced by access, not physiology?
Hamish: Because the registry data won’t tell you that story. It will just show another successful sedation.
Jeremy: So the ICU model gives us a powerful lesson: safety through rescue works extraordinarily well. But it can also mask how close you’re running to the edge.
Hamish: And if you don’t surface that reality, you end up with a system that looks robust right up until the day it isn’t.
Jeremy: Which brings us to the group that rarely tolerates that ambiguity at all.
Hamish: Anesthesiology.
Jeremy: Where the approach to sedation is often to eliminate drift entirely — even if that means accepting different costs.
Jeremy: If the ICU model is about managing drift, anesthesiology often takes a different approach.
Hamish: It removes drift entirely.
Jeremy: Exactly. In many anesthesiology-led sedation models, particularly in the UK and parts of the US, there’s an implicit philosophy: if there’s a meaningful chance this will become deep sedation, we may as well treat it as anaesthesia from the outset.
Hamish: Which is why so many of these cases end up with an LMA, or even an endotracheal tube, despite being labelled “sedation.”
Jeremy: And from a safety standpoint, it’s incredibly effective. The serious adverse event rates are almost vanishingly small. Aspiration is rare. Hypoxia is anticipated. Airway emergencies are resolved before they escalate.
Hamish: Because they’re not really emergencies — they’re planned contingencies.
Jeremy: Right. The airway is owned from the start. There’s no ambiguity about who rescues if something goes wrong.
Hamish: And that clarity is seductive. Especially for governance. If you’re a hospital executive looking at safety dashboards, anesthesiology-led sedation looks like the gold standard. Near-zero harm. Clean metrics. Minimal surprises.
Jeremy: But that’s not the whole story.
Hamish: No, because the safety doesn’t come for free. It comes with cost, capacity implications, and opportunity cost that often sits outside the sedation outcome metrics.
Jeremy: Let’s unpack that.
Hamish: First, resource intensity. An anesthetist, an anaesthetic assistant, theatre-grade monitoring, recovery space. Even when the procedure itself is minor, the surrounding machinery is substantial.
Jeremy: Which means access becomes the limiting factor.
Hamish: Exactly. Children wait. Procedures get delayed. EDs hold onto patients longer. Lists get reshuffled. And none of that shows up as a sedation complication — but it absolutely shows up elsewhere in the system.
Jeremy: There’s also a philosophical cost. When anesthesia becomes the default, we quietly narrow the skill set of everyone else.
Hamish: That’s the part people don’t like to talk about. ED and ICU clinicians stop doing certain sedations, not because they can’t, but because they’re no longer allowed to. Skills atrophy. Confidence erodes.
Jeremy: And paradoxically, that can make the system less resilient.
Hamish: Yes. Because when anesthesia isn’t immediately available — after hours, in smaller centres, during surge — the system suddenly discovers it has fewer people willing to take on that risk.
Jeremy: I’ll challenge you there. Isn’t that just appropriate risk containment? Let the people who do airways all day do the airways.
Hamish: It sounds reasonable — until you realise you’ve turned anesthesiology into a single point of failure. The system works beautifully when capacity is abundant, and poorly when it isn’t.
Jeremy: And the data won’t warn you.
Hamish: No. Because again, the sedation outcomes are pristine. The harm shows up as delays, transfers, cancellations, and distressed families — not as adverse event reports.
Jeremy: There’s also a subtle moral hazard here.
Hamish: Absolutely. When anesthesia absorbs the highest-risk cases, everyone else’s outcomes look better. Which can make comparative safety discussions misleading.
Jeremy: Because the ED or ICU models look “almost as safe” — without acknowledging they’re dealing with a different risk mix.
Hamish: And that matters when leaders start making policy decisions based solely on headline rates.
Jeremy: So anesthesiology-led sedation gives us something invaluable: a demonstration of what near-zero harm looks like when airway ownership is absolute.
Hamish: But it also forces a hard question. How much capacity are you willing to spend to buy that last fraction of a percent of safety — and what are you willing to give up elsewhere to afford it?
Jeremy: And importantly, is that decision being made consciously, or by default?
Hamish: Because systems drift just like patients do.
Jeremy: Which brings us to the data itself. Because once you line these models up side by side, patterns start to emerge about what actually goes wrong — and what almost never does.
Hamish: And that’s where the story gets really interesting.
Jeremy: By this point, it’s tempting to say: look, whichever model you choose — ED, ICU, anesthesiology — pediatric procedural sedation is just very safe.
Hamish: And that’s true. But it’s also incomplete.
Jeremy: Because “safe” depends on what you’re counting.
Hamish: Exactly. When you actually look at the data across regions, a very consistent pattern emerges. The vast majority of adverse events are respiratory. Desaturation. Hypoventilation. Airway obstruction. Brief apnea.
Jeremy: And they’re usually transient.
Hamish: Yes. A jaw thrust. A bit of positive pressure. Oxygen back on. Everyone relaxes. The procedure continues.
Jeremy: Which is why they’re often described as minor.
Hamish: But minor doesn’t mean meaningless. These events are signals. They tell you where the edge of safety really is.
Jeremy: And importantly, they tell you how close you’re running to it.
Hamish: Across ED, ICU, and anesthesia-led sedation, oxygen desaturation happens in somewhere between one and five percent of cases, depending on the drug and context. Vomiting is just as common. Agitation a bit less so.
Jeremy: What almost never happens — and this is worth emphasising — is aspiration, cardiac arrest, or death. Across tens of thousands of sedations, those outcomes are either vanishingly rare or completely absent.
Hamish: Which should reassure people — but not lull them into complacency.
Jeremy: Because the absence of catastrophic outcomes isn’t an accident. It’s the result of early recognition and effective rescue.
Hamish: And that rescue is not evenly distributed. It depends on staffing, experience, monitoring, and time of day.
Jeremy: There’s also a drug story here.
Hamish: Yes. Single-agent ketamine consistently performs best in ED settings. The moment you add a second depressant — an opioid, a benzodiazepine, or propofol — the rate of respiratory events goes up.
Jeremy: Not dramatically — but predictably.
Hamish: Which is why many of the worst historical sedation disasters didn’t involve exotic drugs or massive overdoses. They involved combinations that quietly stacked respiratory depression.
Jeremy: And that lesson has largely been learned.
Hamish: Mostly. But combination regimens still creep back in under pressure. Long procedures. Agitated children. A desire to “smooth things out.”
Jeremy: There’s also a group of adverse events that almost never make the slides.
Hamish: Yes — the near-misses that don’t meet reporting thresholds. The moment when the capnography trace flattens before the saturation drops. The child who obstructs when repositioned. The emesis that’s suctioned before it matters.
Jeremy: Those moments are invisible to the system.
Hamish: But they’re very visible to the clinician at the bedside.
Jeremy: This is where evidence honesty is important. We have excellent observational data. We do not have randomised trials comparing ED versus ICU versus anesthesia-led sedation on hard outcomes — because the event rates are too low.
Hamish: So when we say one model is “safer” than another, what we really mean is that it produces fewer recognised adverse events — not necessarily that it carries less latent risk.
Jeremy: And latent risk is what systems leaders need to care about.
Hamish: Because latent risk accumulates quietly. It shows up when staffing thins, when experience drops, and when volume increases.
Jeremy: So the real takeaway from the adverse event data isn’t that sedation is benign.
Hamish: It’s that modern sedation safety depends on constant vigilance — and that vigilance has a human cost.
Jeremy: Which naturally leads us to the moments when that vigilance almost isn’t enough.
Hamish: The failure modes.
Jeremy: The near-misses that don’t make headlines — but should shape policy.
Jeremy: Let’s talk about the cases that never become cases.
Hamish: The ones that don’t get written up.
Jeremy: Exactly. Because if you only look at incident reports, pediatric procedural sedation looks almost flawless.
Hamish: But if you listen to clinicians — really listen — a different picture emerges.
Jeremy: So let’s run through a scenario. Not a horror story. Just a Tuesday.
Hamish: Non-intubated child. Moderate physiological reserve. Needs a painful procedure. Sedation starts smoothly. Single agent. Monitoring on. Everyone relaxed.
Jeremy: Then a subtle change. Capnography dampens. Chest movement becomes shallow. Saturations start drifting — not crashing, just sliding
Hamish: Someone notices. Jaw thrust. Oxygen up. A few assisted breaths.
Jeremy: The child recovers. Procedure continues. No escalation. No intubation. No incident form.
Hamish: From the system’s point of view, nothing happened.
Jeremy: From the clinician’s point of view, that was a near-miss.
Hamish: And the reason it didn’t become more than that wasn’t luck. It was vigilance, experience, and spare cognitive capacity.
Jeremy: Now here’s the uncomfortable part. That spare capacity isn’t guaranteed.
Hamish: No. It depends on who’s in the room, how many other things they’re holding in their head, and how noisy the environment is — cognitively and literally.
Jeremy: And these near-misses cluster. They happen at the end of long shifts. Overnight. When staffing is thin. When the most experienced clinician is supervising three things at once.
Hamish: This is where I’ll push back against the narrative that “good training solves this.” Training matters — but it doesn’t eliminate cognitive load.
Jeremy: Agreed. You can’t train your way out of system pressure.
Hamish: And the data won’t save you either. Because near-misses don’t move the needle on outcome dashboards.
Jeremy: Which means they don’t trigger a system change.
Hamish: Exactly. Instead, clinicians adapt. They become hyper-vigilant. They cut corners elsewhere. They normalise the edge.
Jeremy: And that adaptation is fragile. It works — until it doesn’t.
Hamish: This is why many historical sedation catastrophes weren’t caused by ignorance or recklessness. They were caused by drift. Small deviations becoming normal practice, unchallenged because nothing bad had happened yet.
Jeremy: And when something finally does happen, the system is shocked.
Hamish: As if the warning signs weren’t there all along.
Jeremy: So the failure mode isn’t “sedation is dangerous.”
Hamish: No. The failure mode is that sedation safety is maintained by invisible work, and invisible work is easy to take for granted.
Jeremy: Which brings us to drug choice — because some choices reduce the burden of that invisible work more than others.
Hamish: And some make it heavier.
Jeremy: So let’s talk about why, across almost every dataset, simpler drug strategies keep outperforming more complex ones.
Jeremy: If you step back from individual cases and look across regions, settings, and years, one pattern is almost embarrassingly consistent.
Hamish: The simplest drug strategies perform the best.
Jeremy: Single-agent ketamine in the ED. Nitrous oxide for brief procedures. Propofol alone, when delivered by teams built to handle it. Over and over again, complexity correlates with risk.
Hamish: And that’s not because clinicians are careless with combinations. It’s because combinations increase cognitive load and narrow margins.
Jeremy: Each additional drug adds a second set of kinetics, interactions, and failure modes.
Hamish: And more importantly, it muddies ownership. When something goes wrong, it’s harder to know why. Was it the ketamine? The opioid? The timing? The cumulative effect?
Jeremy: Which makes learning harder.
Hamish: Exactly. Single-agent strategies are easier to reason about, teach, standardise, and govern.
Jeremy: That’s why ketamine has become such a dominant agent in ED sedation globally.
Hamish: Not because it’s perfect — vomiting and emergence reactions are real — but because it gives you a wide safety margin where airway reflexes and cardiovascular stability are preserved.
Jeremy: And nitrous oxide plays a similar role at the lighter end of the spectrum.
Hamish: Yes. Nitrous is interesting because it’s not just a drug — it’s a constraint. It caps how deep you can go. That forces clinicians to think carefully about case selection and escalation.
Jeremy: Whereas propofol, by design, removes that cap.
Hamish: Which is why propofol performs beautifully in systems built around airway ownership and rescue—and less well when those assumptions aren’t met.
Jeremy: This is where I’ll challenge a common narrative. People often talk about “advanced” sedation as if it’s inherently better.
Hamish: But advanced for whom?
Jeremy: Exactly. Advanced pharmacology without advanced systems is a mismatch.
Hamish: And that mismatch shows up in the data. The risk signal increases when propofol is used outside anesthesia or ICU contexts without equivalent scaffolding.
Jeremy: Which leads to an uncomfortable leadership question.
Hamish: Yes. When a hospital allows or encourages more complex sedation strategies, is it also investing proportionally in training, staffing, and governance?
Jeremy: Or is it simply shifting risk onto individual clinicians?
Hamish: Because drug choice isn’t neutral. It encodes assumptions about who will rescue, how quickly, and with what support.
Jeremy: So when we say “ketamine is safer,” what we often mean is “ketamine is safer in the systems we actually have.”
Hamish: Exactly. And that distinction matters.
Jeremy: It also explains why newer agents, such as dexmedetomidine, have found a niche.
Hamish: Yes — not because they’re miracle drugs, but because they trade depth for predictability. Less respiratory depression, slower onset, more time to react.
Jeremy: Again, a governance choice.
Hamish: And a reminder that safety isn’t about eliminating risk — it’s about making risk legible and manageable.
Jeremy: Which brings us to training and protocols.
Hamish: Because once you move beyond drug choice, the next question is whether standardisation actually delivers the safety we think it does.
Jeremy: If you listen to how organisations talk about sedation safety, there’s a familiar refrain.
Hamish: Training. Protocols. Checklists.
Jeremy: And to be clear — all of those matter. They’re foundational. No one here is arguing against them.
Hamish: But the data — and lived experience — suggest they’re necessary, not sufficient.
Jeremy: Because standardisation works beautifully for predictable problems.
Hamish: And sedation isn’t always predictable.
Jeremy: Exactly. The moment a child obstructs, vomits, or slips deeper than intended, you’re no longer following a flowchart. You’re improvising.
Hamish: Which is why two departments can have identical protocols and very different outcomes.
Jeremy: Because what really matters is how those protocols are inhabited.
Hamish: Training tells you what to do. Experience tells you when the situation is about to change.
Jeremy: And protocols don’t reduce cognitive load as much as we pretend they do.
Hamish: Sometimes they increase it. Multiple checkboxes. Multiple monitors. Multiple escalation criteria.
Jeremy: Which creates a paradox. The safer we try to make sedation on paper, the more mental bandwidth it can consume at the bedside.
Hamish: And clinicians adapt. They skim. They shortcut. They rely on pattern recognition.
Jeremy: Not because they’re reckless — but because they’re human.
Hamish: This is where I’ll push back slightly. Without protocols, variability explodes. And variability is dangerous.
Jeremy: Agreed. But protocol rigidity is dangerous too.
Hamish: Exactly. The sweet spot is not maximal standardisation, it’s adaptive standardisation.
Jeremy: Meaning?
Hamish: Clear minimum standards. Clear red lines. And explicit permission to escalate early without stigma.
Jeremy: Which is something protocols often fail to encode.
Hamish: Yes. Many protocols describe what “should” happen, but not what to do when reality diverges.
Jeremy: And that divergence is where harm either occurs or is prevented.
Hamish: Another uncomfortable truth: training is uneven. Simulation helps, but real sedation experience still clusters in certain clinicians.
Jeremy: Which means systems that assume uniform competence are fooling themselves.
Hamish: And potentially exposing their least experienced staff to the highest cognitive burden.
Jeremy: So when leaders say, “We have a protocol,” the real question is: does that protocol acknowledge human variability, or does it pretend it doesn’t exist?
Hamish: Because sedation safety lives in the gaps — not the documents.
Jeremy: Which brings us to data.
Hamish: Because some systems try to close those gaps by measuring everything.
Jeremy: And that strategy has its own trade-offs.
Jeremy: If there’s one place where pediatric procedural sedation has evolved dramatically in the last decade, it’s in measurement.
Hamish: Especially in the United States. Large registries. Standardised adverse event definitions. Hundreds of thousands of cases logged, analysed, and fed back into practice.
Jeremy: And to be clear, that’s been transformative. Without those registries, we wouldn’t know half of what we now take for granted. Which drugs perform best? Which combinations increase risk? Which patient groups deserve extra caution?
Hamish: Absolutely. The decline of older, riskier sedatives didn’t happen because of intuition. It happened because the data made the risk undeniable.
Jeremy: And registry data has given leaders confidence that sedation outside the OR can be safe, which has unlocked access, reduced delays, and spared many children general anaesthesia.
Hamish: But measurement has side effects.
Jeremy: Go on.
Hamish: What you choose to measure shapes behaviour. And sedation registries, by necessity, focus on recognised adverse events.
Jeremy: Desaturation below a threshold. Unplanned airway intervention. Aspiration. Arrest.
Hamish: Exactly. What they struggle to capture is the cognitive work that prevents those events from happening.
Jeremy: The anticipatory jaw thrust. The early decision to stop. The moment someone says, “This doesn’t feel right.”
Hamish: Those actions erase the adverse event, which means they also erase the signal.
Jeremy: So paradoxically, the better clinicians get at rescue, the safer the data looks.
Hamish: And the less urgency there appears to be for system change.
Jeremy: This is where I’ll defend registries a bit. Without them, we’d be flying blind
Hamish: I agree. The problem isn’t data — it’s overconfidence in what data represents.
Jeremy: Because registries are very good at answering: “How often did something bad happen?”
Hamish: But much worse at answering: “How close did we come?”
Jeremy: And leaders make decisions based on the first question, not the second.
Jeremy: Which can drive subtle pressure. More cases. Broader indications. Fewer exclusions.
Jeremy: Because the numbers look safe.
Hamish: Exactly. This is where measurement can unintentionally enable moral hazard. Safety metrics become a justification for stretching the system further.
Jeremy: And stretching always shows up first as cognitive load, not complications.
Hamish: Which registries don’t capture.
Jeremy: Another issue is ownership. When outcomes are aggregated across services, responsibility can diffuse.
Hamish: Yes. A complication becomes “a system rate,” rather than a moment that demands local reflection.
Jeremy: Or worse — near-misses vanish entirely.
Hamish: So the most mature systems don’t just collect data — they contextualise it.
Jeremy: They ask not just what happened, but under what conditions.
Hamish: Staffing levels. Time of day. Experience mix. Competing demands.
Jeremy: Which brings us back to leadership again.
Hamish: Because data doesn’t make systems safer on its own. Leaders decide how it’s interpreted, what it’s used to justify, and what it’s allowed to obscure.
Jeremy: And that sets the stage for one of the most uncomfortable parts of this conversation.
Hamish: Moral hazard.
Jeremy: Yes. When success quietly creates new risk.
Jeremy: There’s a paradox that keeps showing up in high-reliability systems.
Hamish: The safer something becomes, the more we ask it to do.
Jeremy: Exactly. And pediatric procedural sedation is a textbook example.
Hamish: Because when complication rates are low, sedation starts to look like a solution to problems it was never designed to solve.
Jeremy: Throughput. Access. Theatre bottlenecks. Staffing gaps.
Hamish: Yes. “We can just sedate them in ED.”“We can do it in ICU instead of waiting for a list.”“We don’t need anaesthetics for this anymore.”
Jeremy: Each decision makes sense in isolation.
Hamish: But collectively, they stretch the system.
Jeremy: And that stretch rarely shows up as harm in the sedation data.
Hamish: No. It shows up as clinicians holding more risk, more often, with fewer buffers.
Jeremy: This is where sedation becomes a shock absorber for system failure.
Hamish: And shock absorbers wear out.
Jeremy: I want to be careful here, because this can sound like we’re arguing for pulling back sedation access.
Hamish: We’re not. We’re arguing for honesty about what sedation is compensating for.
Jeremy: Because when sedation fills gaps created by inadequate theatre access, insufficient anaesthetic staffing, or unrealistic throughput targets, the risk doesn’t disappear.
Hamish: It just lands on the clinician at the bedside.
Jeremy: And often without explicit acknowledgement.
Hamish: Which creates a moral hazard. The organisation benefits from smoother flow and cleaner metrics, while the clinician absorbs the stress, vigilance, and liability.
Jeremy: And when something does go wrong — even rarely — the narrative often focuses on individual decision-making rather than system design.
Hamish: That’s the part that should worry leaders.
Jeremy: Because systems that rely on silent heroism are brittle.
Hamish: And they tend to fail suddenly, not gradually.
Jeremy: There’s also an equity issue here.
Hamish: Absolutely. Smaller centres, after-hours teams, and less experienced staff are often asked to do more with less — under the banner of “it’s safe.”
Jeremy: Because the data came from tertiary centres with depth, redundancy, and support.
Hamish: Which doesn’t always translate.
Jeremy: So the uncomfortable question becomes: when we celebrate low complication rates, are we also checking whether we’re normalising unsafe levels of cognitive and moral load?
Hamish: And whether we’ve quietly shifted responsibility without redistributing authority or resources.
Jeremy: Because if leadership distributes risk without distributing support, clinicians become the final safety net.
Hamish: And no system should rely on that indefinitely.
Jeremy: Which brings us directly to governance.
Hamish: Because moral hazard only persists when responsibility is blurred.
Jeremy: So the next question is simple — and confronting.
Hamish: Who actually owns the airway, the decision, and the consequence?
Jeremy: Up to this point, we’ve talked a lot about models, data, and behaviour. But underneath all of it is a much simpler question.
Hamish: Who owns the airway when things start to drift?
Jeremy: And ownership isn’t just about skill. It’s about authority.
Hamish: Exactly. Who is empowered to say, “This stops now,” and escalate — without needing permission, justification, or hindsight defence
Jeremy: In anesthesiology-led models, that ownership is explicit. The airway belongs to the anesthetist. Escalation is expected. Converting to general anaesthesia is not a failure — it’s the plan.
Hamish: Which makes liability clean. Decisions are clear. Governance is straightforward.
Jeremy: In ICU-led models, ownership is usually shared — but still visible. The team has airway capability. Escalation pathways are close. Authority is embedded in the role.
Hamish: But in ED-led sedation, ownership can become ambiguous.
Jeremy: Not because ED clinicians lack skill — they don’t — but because the boundaries are less clearly drawn.
Hamish: Exactly. The ED clinician is sedating, monitoring, managing the department, supervising juniors, answering phones. Authority is distributed — sometimes thinly.
Jeremy: And escalation often involves calling someone else.
Hamish: Which introduces friction. Time. Social dynamics. Perceived thresholds.
Jeremy: This is where governance quietly shapes behaviour.
Hamish: Yes. If escalation is culturally framed as “calling for help,” people wait longer than they should.
Jeremy: Whereas if it’s framed as “handing over risk,” people escalate earlier.
Hamish: And the data won’t tell you which culture you have.
Jeremy: Because both cultures can produce excellent outcomes — until they don’t.
Hamish: Another uncomfortable layer here is liability.
Jeremy: Go on.
Hamish: When sedation is successful, ownership feels diffuse. When something goes wrong, it snaps sharply into focus.
Jeremy: Often onto the individual clinician.
Hamish: Especially if escalation thresholds were informal rather than codified.
Jeremy: This is where leaders need to be honest with themselves.
Hamish: If your system encourages clinicians to push sedation further to meet access or throughput goals, but doesn’t explicitly back them when escalation is needed, you’ve created a liability trap.
Jeremy: And those traps are rarely intentional.
Hamish: But they are predictable.
Jeremy: So good governance doesn’t just say who can sedate. It says who must take over when sedation drifts.
Hamish: And it makes that transition socially easy, operationally fast, and professionally safe.
Jeremy: Which brings us to the final piece.
Hamish: The Monday morning question.
Jeremy: Yes. Because after all of this, people will want to know what to actually do.
Jeremy: So imagine it’s Monday morning. You’re back at work. Your inbox is full. And someone has just sent you a proposal
Hamish: “Expand pediatric procedural sedation access.”
Jeremy: Exactly. More cases in the ED. More ICU-led sedation. Fewer theatre bookings. On paper, it looks efficient, safe, and evidence-based.
Hamish: And the data will support it.
Jeremy: Yes, which is why this decision is dangerous if it’s made too quickly.
Hamish: Because the right question isn’t “Is sedation safe?” We know it is.
Jeremy: The right question is: what assumptions are we making about who will absorb the risk when it isn’t?
Hamish: So here’s a practical starting point. Before you expand sedation access, ask: Who owns escalation at 2 a.m. on a weekend?
Jeremy: And is that ownership real, or theoretical?
Hamish: Because if the answer is “the most senior clinician in the room,” but that clinician is covering three areas and supervising two juniors, you don’t actually have ownership — you have hope.
Jeremy: Another hard question: are you expanding sedation because it’s clinically appropriate, or because it’s compensating for a capacity problem elsewhere?
Hamish: Because if it’s the latter, sedation is acting as a pressure valve — and pressure valves fail silently until they don’t.
Jeremy: Here’s where I’ll push back slightly. There are cases where expanding sedation is exactly the right thing to do.
Hamish: I agree. But only if you expand the scaffolding at the same time.
Jeremy: Training, staffing, simulation, escalation pathways.
Hamish: And explicit permission to stop.
Jeremy: Yes. Leaders underestimate how powerful that is.
Hamish: If clinicians believe that aborting a sedation and calling for help will be questioned later, they will push further than they should.
Jeremy: Which is how near-misses turn into incidents.
Hamish: So one of the most impactful things leaders can do is say, clearly and repeatedly: escalation is success, not failure.
Jeremy: And then back that statement up when it’s tested.
Hamish: Another uncomfortable decision: not every centre needs to do everything.
Jeremy: That’s hard to hear.
Hamish: But honestly. Volume, experience, and support matter. A model that works safely in a tertiary children’s hospital may not translate cleanly to a small regional ED.
Jeremy: So sometimes the right decision is not expansion — but clarity about limits.
Hamish: Which takes courage.
Jeremy: And finally, leaders should look beyond complication rates.
Hamish: Ask about near-misses. Ask about cognitive load. Ask clinicians how close things feel to the edge.
Jeremy: Because if the answer is “we’re fine,” that’s reassuring.
Hamish: But if the answer is “we’re coping,” that’s a warning.
Jeremy: Sedation safety today is one of medicine’s quiet successes. But its success rests on invisible work.
Jeremy: And invisible work is easy to exploit.
Hamish: So the challenge for leaders isn’t to make sedation safer.
Jeremy: It’s to make the systems around it more honest.
Jeremy: Pediatric procedural sedation hasn’t become safe because we eliminated risk. It’s become safe because we learned how to recognise it early, manage it well, and rescue effectively. The danger now is forgetting that lesson.
Hamish: Because the moment we treat safety as a property of drugs or protocols, rather than people and systems, we start to drift.
Jeremy: And drift is exactly what sedation safety was designed to prevent.
Hamish: That’s where we’ll leave it.
Jeremy: Thanks for listening to The TIME Podcast.
Hamish: And we’ll see you at the TIME Conference.
